Teladoc Health Inc (NYSE:TDOC) has been assigned a consensus recommendation of “Buy” from the twenty-three analysts that are currently covering the company, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, five have assigned a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among brokers that have issued a report on the stock in the last year is $81.95.
A number of research analysts recently issued reports on TDOC shares. Cantor Fitzgerald restated a “hold” rating and set a $52.00 price objective on shares of Teladoc Health in a report on Wednesday, August 1st. Wells Fargo & Co restated a “buy” rating and set a $70.00 price objective on shares of Teladoc Health in a report on Thursday, August 2nd. KeyCorp boosted their price objective on shares of Teladoc Health from $74.00 to $90.00 and gave the company an “overweight” rating in a report on Monday, August 27th. MED boosted their price objective on shares of Teladoc Health from $68.00 to $89.00 and gave the company an “outperform” rating in a report on Friday, September 28th. Finally, Citigroup boosted their price objective on shares of Teladoc Health from $80.00 to $88.00 and gave the company a “buy” rating in a report on Friday, September 21st.
In other news, insider Adam C. Vandervoort sold 5,549 shares of the business’s stock in a transaction on Wednesday, August 8th. The shares were sold at an average price of $67.25, for a total value of $373,170.25. Following the sale, the insider now owns 2,934 shares of the company’s stock, valued at $197,311.50. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, VP Mark Hirschhorn sold 35,000 shares of the business’s stock in a transaction on Tuesday, September 25th. The stock was sold at an average price of $80.42, for a total transaction of $2,814,700.00. Following the completion of the sale, the vice president now directly owns 10,000 shares in the company, valued at approximately $804,200. The disclosure for this sale can be found here. In the last ninety days, insiders sold 131,706 shares of company stock worth $9,953,679. Insiders own 3.95% of the company’s stock.
Shares of NYSE:TDOC traded up $3.89 during trading on Thursday, hitting $70.26. 74,511 shares of the company’s stock were exchanged, compared to its average volume of 1,273,964. Teladoc Health has a 1-year low of $27.30 and a 1-year high of $89.05. The company has a debt-to-equity ratio of 0.58, a current ratio of 3.14 and a quick ratio of 3.14. The stock has a market cap of $6.01 billion, a price-to-earnings ratio of -42.08 and a beta of 0.57.
Teladoc Health (NYSE:TDOC) last issued its quarterly earnings results on Wednesday, August 1st. The health services provider reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.38) by $0.01. Teladoc Health had a negative net margin of 37.78% and a negative return on equity of 19.10%. The company had revenue of $94.60 million during the quarter, compared to analysts’ expectations of $91.56 million. During the same quarter in the previous year, the company earned ($0.28) EPS. Teladoc Health’s revenue was up 112.1% on a year-over-year basis. Equities research analysts anticipate that Teladoc Health will post -1.51 earnings per share for the current year.
About Teladoc Health
Teladoc Health, Inc provides telehealth services worldwide. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.
Read More: Dividend Aristocrat Index
Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.